Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 12:34 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 85,859 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1 Clear all
Terminated Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

NCT00023790
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Nov 3, 2026, 12:34 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET

NCT01719497
View directory record Official record
Conditions
Obesity, Alcohol Dependence, High Stress
Interventions
[C-11]OMAR
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Nov 3, 2026, 12:34 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

NCT04131413
View directory record Official record
Conditions
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions
pNGVL4aCRTE6E7L2
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 3, 2026, 12:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Communicating Objective Risk for Personalized Decision Making About Mammography

NCT01686360
View directory record Official record
Conditions
Breast Cancer
Interventions
Decision Aid
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
35 Years to 49 Years · Female only
Enrollment
1,560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Nov 3, 2026, 12:34 PM EST
Completed Phase 3 Interventional Results available

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

NCT03301220
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Daratumumab SC: daratumumab + rHuPH20
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
23
States / cities
Phoenix, Arizona • Whittier, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 3, 2026, 12:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing a Patient Navigation Intervention for PrEP Continuum of Care Among Young Latino MSM (PrEParate)

NCT04048382
View directory record Official record
Conditions
HIV/AIDS
Interventions
Patient Navigation, Usual Care
Behavioral · Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 29 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Nov 3, 2026, 12:34 PM EST
Terminated No phase listed Observational

Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

NCT04201782
View directory record Official record
Conditions
HIV-1-infection
Interventions
There are no disallowed treatments
Drug
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
4
States / cities
San Francisco, California • Norwalk, Connecticut • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Nov 3, 2026, 12:34 PM EST
Terminated Phase 2 Interventional

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer

NCT02910882
View directory record Official record
Conditions
Pancreatic Adenocarcinoma Non-resectable
Interventions
PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation
Drug · Radiation
Lead sponsor
Scripps Health
Other
Eligibility
Up to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Nov 3, 2026, 12:34 PM EST
Completed Phase 1 Interventional

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

NCT00323323
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
CHOP, Alemtuzumab, Plasma Samples
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Nov 3, 2026, 12:34 PM EST
Recruiting Phase 2 Interventional

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359
View directory record Official record
Conditions
IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN), IC-MPGN
Interventions
ADX-038 Dose Level 2, ADX-038 Dose Level 1
Drug
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Doral, Florida • Miami, Florida • Pembroke Pines, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 3, 2026, 12:34 PM EST
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

NCT01189279
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 64 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Nov 3, 2026, 12:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

NCT01479296
View directory record Official record
Conditions
HIV Infections
Interventions
VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C), rAd5 env A, rAd5 env B, rAd5 env C, rAd5 gag-pol, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Nov 3, 2026, 12:34 PM EST
Completed Not applicable Interventional

An Intervention to Promote Oral Agent Adherence and Symptom Management: ADHERE

NCT02337296
View directory record Official record
Conditions
Cancer
Interventions
ADHERE
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Jackson, Michigan • Port Huron, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Nov 3, 2026, 12:34 PM EST
Recruiting Phase 1Phase 2 Interventional

Intestinal Microbiome Transplant in ALS

NCT07017946
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis ALS
Interventions
MTP-101C
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 3, 2026, 12:34 PM EST
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

NCT01119846
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Nov 3, 2026, 12:34 PM EST
Completed Phase 2 Interventional

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

NCT00183261
View directory record Official record
Conditions
HIV Infections
Interventions
MRKAd5 HIV-1 gag/pol/nef, MRKAd5 HIV-1 gag/pol/nef placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
13
States / cities
San Diego, California • San Francisco, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 3, 2026, 12:34 PM EST
Completed Not applicable Interventional

Contingency Management for Chronic Recidivist Alcohol-Dependent Patients

NCT00408161
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Contingency Management, standard case management treatment
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Nov 3, 2026, 12:34 PM EST
Completed Phase 2 Interventional Results available

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT02098161
View directory record Official record
Conditions
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Nov 3, 2026, 12:34 PM EST
Completed No phase listed Observational Results available

Controlled Attenuation Parameter (CAP) in Liver Allografts

NCT02798861
View directory record Official record
Conditions
Liver Transplant, Liver Steatosis, Liver Disease, Primary Non-function, Early Allograft Dysfunction
Interventions
Fibroscan 402/530
Device
Lead sponsor
Andres Duarte-Rojo
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Little Rock, Arkansas • Stanford, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Nov 3, 2026, 12:34 PM EST
Completed No phase listed Observational

MERITnI - Mindray-hs-cTnI Assay: Analytical and Clinical Evaluation for the Diagnosis and RIsk AssessmenT of Myocardial InfarctIon.

NCT05853042
View directory record Official record
Conditions
Acute Myocardial Infarction, Acute Coronary Syndrome
Interventions
high-sensitivity cardiac troponin testing
Diagnostic Test
Lead sponsor
Fred Apple
Other
Eligibility
21 Years and older
Enrollment
1,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 3, 2026, 12:34 PM EST
Completed Phase 1 Interventional

ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

NCT01110486
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ABT-348, ABT-348 and carboplatin, ABT-348 and docetaxel
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Nov 3, 2026, 12:34 PM EST
Not listed Not applicable Interventional

Use of AC5® Advanced Wound System in the Treatment of Diabetic Foot Ulcers

NCT06028386
View directory record Official record
Conditions
Non-healing Wound, Diabetic Foot Ulcer
Interventions
AC5® Advanced Wound System, Fibracol Plus Collagen Dressing
Device
Lead sponsor
Arch Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Greenville, North Carolina • Circleville, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Nov 3, 2026, 12:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection

NCT00829686
View directory record Official record
Conditions
Abscess
Interventions
Septra
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Nov 3, 2026, 12:34 PM EST
Completed Phase 2 Interventional Results available

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

NCT03982186
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA)
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
18 Years to 65 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Nov 3, 2026, 12:34 PM EST